ClinicalTrials.gg
CompletedNCT04656418Updated Jun 29, 2023Results posted

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

A Phase 3 interventional study of CSL312 and Placebo in Hereditary Angioedema, sponsored by CSL Behring. Completed at 28 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.

Started
2021
with 1 other
Phase 3
5 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 6th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angioedemas, Hereditary by CSL Limited, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema.

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 12 years of age; diagnosed with clinically confirmed C1-INH hereditary angioedema; experience ≥ 3 attacks during the 3 months before screening.

Note: For subjects taking any prophylactic HAE therapy during the 3 months before Screening, ≥ 3 HAE attacks may be documented over 3 consecutive months before commencing the prophylactic therapy.

Exclusion criteria

Exclusion Criteria:

  • Concomitant diagnosis of another form of angioedema such as idiopathic or acquired angioedema, recurrent angioedema associated with urticarial or hereditary angioedema type 3
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    CSL312

    Participants received a CSL312 loading dose of 400 mg as two 200 mg SC injections in Month 1 along with CSL312 of 200 mg subcutaneous (SC) injections, once monthly from Months 2 to 6.

    Biological: CSL312

  • Placebo comparator
    Placebo

    Participants received a CSL312 matched loading dose of placebo as two SC injections in Month 1 along with CSL312 matched placebo SC injections, once monthly from Months 2 to 6.

    Drug: Placebo

Interventions

  • BiologicalCSL312

    Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody

    Also known as: Factor XIIa inhibitor monoclonal antibody, garadacimab

  • DrugPlacebo

    Buffer without active ingredient

06

What researchers measure

Primary outcomes

  1. Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period

    Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

    Time frame: First injection up to 6 months

Secondary outcomes

  1. Percentage Change in the Time-normalized Number of HAE Attacks Per Month During the Treatment Period Compared to the Run-in Period

    Percentage change in the time-normalized number of HAE attacks was calculated within a participant as: 100 \* \[1 - (time-normalized number of HAE attacks per month during treatment period / time-normalized number of HAE attacks per month during run-in period)\]. Time-normalized number of HAE attacks per month during treatment period was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

    Time frame: 6 months, first 3-months and second 3-months of treatment period

  2. Time-Normalized Number of HAE Attacks Per Month Requiring On-Demand Treatment

    Time-normalized number of HAE attacks per month requiring on-demand treatment was calculated per participant as: \[number of HAE attacks requiring on-demand treatment / length of participant in days\] \* 30.4375.

    Time frame: 6 months, first 3-months and second 3-months of treatment period

  3. Time-Normalized Number of Moderate or Severe HAE Attacks Per Month

    Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.

    Time frame: 6 months, first 3-months and second 3-months of treatment period

  4. Time-normalized Number of HAE Attacks Per Month in the First 3-months and Second 3-months of Treatment Period

    Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

    Time frame: First 3-months and second 3-months of treatment period

  5. Relative Difference in Means in the Time-Normalized Number of HAE Attacks Per Month Between CSL312 to Placebo

    Relative difference in means in the time-normalized number of HAE attacks per month CSL312 to Placebo was calculated as: 100 \* \[(mean time-normalized number of HAE attacks for CSL312 - mean time-normalized number of HAE attacks for placebo) / mean time-normalized number of HAE attacks for placebo\]. Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

    Time frame: 6 months, first 3-months and second 3-months of treatment period

  6. Percentage of Participants With a Response to Subject's Global Assessment of Response to Therapy (SGART)

    SGART is a self-assessment by the participant and measures the subject's overall treatment response to the investigational product using the following ratings: 0 (none: worse or no response at all, not acceptable), 1 (poor: very little response, not acceptable), 2 (fair: some response, acceptable but could be better), 3 (good: good response, acceptable), and 4 (excellent: excellent response, as good as can be imagined).

    Time frame: Up to 6 months

  7. Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AEs of Special Interest (AESI)

    AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.

    Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)

  8. Number of Participants With CSL312-induced Anti-CSL312 Antibodies

    Time frame: Up to 8 months

  9. Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as Treatment Emergent Adverse Events (TEAEs)

    Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.

    Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)

  10. Percentage of Participants With at Least One AE, SAE, and AESI

    AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.

    Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)

  11. Percentage of Participants With CSL312-induced Anti-CSL312 Antibodies

    Time frame: Up to 6 months

  12. Percentage of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as TEAEs

    Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.

    Time frame: From first dose of study drug up to 3 months after the last injection (approximately 8 months)

07

Results

Posted Jun 29, 2023

Participant flow

Participants were enrolled at study centers in Canada, Germany, Hungary, Israel, Japan, Netherlands, and the United States from 27 January 2021 to 07 June 2022.

Participant flow — Overall Study
MilestoneCSL312Placebo
Started3925
Intention-to-treat (itt) analysis set3925
Safety analysis set3925
Completed3822
Not completed13
Withdrew: Withdrawal by subject13

Outcome measures

PrimaryTime-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period

Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

Time frame:
First injection up to 6 months
Reported as:
Mean · number of HAE attacks per month
Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period
number of HAE attacks per monthCSL312Placebo
Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period0.27 ± 0.6832.01 ± 1.341
Statistical analysis
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Compared the time-normalized number of HAE attacks in the active and placebo arms by using a two-sided Wilcoxon test (Hierarchical Testing H01) at alpha = 5%.)
SecondaryPercentage Change in the Time-normalized Number of HAE Attacks Per Month During the Treatment Period Compared to the Run-in Period

Percentage change in the time-normalized number of HAE attacks was calculated within a participant as: 100 \* \[1 - (time-normalized number of HAE attacks per month during treatment period / time-normalized number of HAE attacks per month during run-in period)\]. Time-normalized number of HAE attacks per month during treatment period was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

Time frame:
6 months, first 3-months and second 3-months of treatment period
Reported as:
Mean · percentage change in HAE attacks/month
Percentage Change in the Time-normalized Number of HAE Attacks Per Month During the Treatment Period Compared to the Run-in Period
percentage change in HAE attacks/monthCSL312Placebo
6 Months of Treatment90.67 ± 22.43320.21 ± 42.661
First 3-months of Treatment91.10 ± 21.25518.89 ± 53.837
Second 3-months of Treatment90.12 ± 25.62429.87 ± 55.529
Statistical analysis
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Compared the time-normalized number of HAE attacks in the active and placebo arms by using a two-sided Wilcoxon test.)
SecondaryTime-Normalized Number of HAE Attacks Per Month Requiring On-Demand Treatment

Time-normalized number of HAE attacks per month requiring on-demand treatment was calculated per participant as: \[number of HAE attacks requiring on-demand treatment / length of participant in days\] \* 30.4375.

Time frame:
6 months, first 3-months and second 3-months of treatment period
Reported as:
Mean · number of HAE attacks per month
Time-Normalized Number of HAE Attacks Per Month Requiring On-Demand Treatment
number of HAE attacks per monthCSL312Placebo
6 Months of Treatment0.23 ± 0.6631.86 ± 1.412
First 3-months of Treatment0.24 ± 0.7481.76 ± 1.378
Second 3-months of Treatment0.23 ± 0.6101.80 ± 1.626
Statistical analysis
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
SecondaryTime-Normalized Number of Moderate or Severe HAE Attacks Per Month

Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.

Time frame:
6 months, first 3-months and second 3-months of treatment period
Reported as:
Mean · number of HAE attacks per month
Time-Normalized Number of Moderate or Severe HAE Attacks Per Month
number of HAE attacks per monthCSL312Placebo
6 Months of Treatment0.13 ± 0.2961.35 ± 1.166
First 3-months of Treatment0.12 ± 0.3051.25 ± 1.091
Second 3-months of Treatment0.13 ± 0.3201.24 ± 1.296
Statistical analysis
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
SecondaryTime-normalized Number of HAE Attacks Per Month in the First 3-months and Second 3-months of Treatment Period

Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

Time frame:
First 3-months and second 3-months of treatment period
Reported as:
Mean · number of HAE attacks per month
Time-normalized Number of HAE Attacks Per Month in the First 3-months and Second 3-months of Treatment Period
number of HAE attacks per monthCSL312Placebo
First 3-months of Treatment0.26 ± 0.7491.97 ± 1.287
Second 3-months of Treatment0.28 ± 0.6521.86 ± 1.603
Statistical analysis
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
  • CSL312 vs Placebo · Two-sided Wilcoxon test · p = <0.001 (Tested the differences between the active and placebo arms using a two-sided Wilcoxon test at alpha = 5%.)
SecondaryRelative Difference in Means in the Time-Normalized Number of HAE Attacks Per Month Between CSL312 to Placebo

Relative difference in means in the time-normalized number of HAE attacks per month CSL312 to Placebo was calculated as: 100 \* \[(mean time-normalized number of HAE attacks for CSL312 - mean time-normalized number of HAE attacks for placebo) / mean time-normalized number of HAE attacks for placebo\]. Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\] \* 30.4375.

Time frame:
6 months, first 3-months and second 3-months of treatment period
Reported as:
Mean · number of HAE attacks per month
Relative Difference in Means in the Time-Normalized Number of HAE Attacks Per Month Between CSL312 to Placebo
number of HAE attacks per monthCSL312 and Placebo Comparison Group
6 Months of Treatment-86.51 (-95.68 to -57.84)
First 3-months of Treatment-86.64 (-95.87 to -56.76)
Second 3-months of Treatment-85.01 (-95.62 to -48.74)
Statistical analysis
  • CSL312 and Placebo Comparison Group · Two-sided Wilcoxon test · p = <0.001 (Compared the time-normalized number of HAE attacks in the active and placebo arms by using a two-sided Wilcoxon test (Hierarchical testing H02) at alpha = 5%.)
SecondaryPercentage of Participants With a Response to Subject's Global Assessment of Response to Therapy (SGART)

SGART is a self-assessment by the participant and measures the subject's overall treatment response to the investigational product using the following ratings: 0 (none: worse or no response at all, not acceptable), 1 (poor: very little response, not acceptable), 2 (fair: some response, acceptable but could be better), 3 (good: good response, acceptable), and 4 (excellent: excellent response, as good as can be imagined).

Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Response to Subject's Global Assessment of Response to Therapy (SGART)
percentage of participantsCSL312Placebo
None2.641.7
Poor7.916.7
Fair7.98.3
Good15.820.8
Excellent65.812.5
SecondaryNumber of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AEs of Special Interest (AESI)

AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.

Time frame:
From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AEs of Special Interest (AESI)
ParticipantsCSL312Placebo
AE2515
SAE10
AESI00
SecondaryNumber of Participants With CSL312-induced Anti-CSL312 Antibodies
Time frame:
Up to 8 months
Reported as:
Count of participants · Participants
Number of Participants With CSL312-induced Anti-CSL312 Antibodies
ParticipantsCSL312Placebo
Number of Participants With CSL312-induced Anti-CSL312 Antibodies10
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as Treatment Emergent Adverse Events (TEAEs)

Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.

Time frame:
From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as Treatment Emergent Adverse Events (TEAEs)
ParticipantsCSL312Placebo
Number of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as Treatment Emergent Adverse Events (TEAEs)12
SecondaryPercentage of Participants With at Least One AE, SAE, and AESI

AE is any untoward medical occurrence in a participant administered with an investigational product which does not necessarily have a causal relationship with treatment, can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product, whether or not considered related to product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event. An AESI is an AE of scientific and medical concern specific to sponsor's product or program, for which ongoing monitoring and rapid communication by investigator to sponsor is appropriate.

Time frame:
From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One AE, SAE, and AESI
percentage of participantsCSL312Placebo
AE64.160.0
SAE2.60
AESI00
SecondaryPercentage of Participants With CSL312-induced Anti-CSL312 Antibodies
Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With CSL312-induced Anti-CSL312 Antibodies
percentage of participantsCSL312Placebo
Percentage of Participants With CSL312-induced Anti-CSL312 Antibodies2.60
SecondaryPercentage of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as TEAEs

Laboratory assessments included: Hematology, biochemistry, urinalysis, and coagulation parameters.

Time frame:
From first dose of study drug up to 3 months after the last injection (approximately 8 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as TEAEs
percentage of participantsCSL312Placebo
Percentage of Participants With Clinically Significant Abnormalities in Laboratory Assessments Reported as TEAEs2.68.0

Adverse events

Collected over From first dose of study drug up to 3 months after the last injection (approximately 8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CSL3120/39 (0%)1/39 (2.6%)17/39 (43.6%)
Placebo0/25 (0%)0/25 (0%)12/25 (48%)
Most frequent serious events
Most frequent serious events
EventCSL312Placebo
Hereditary angioedemaCongenital, familial and genetic disorders1/390/25
Most frequent other events
Showing 10 of 18
Most frequent other events
EventCSL312Placebo
HeadacheNervous system disorders3/394/25
COVID-19Infections and infestations0/393/25
FatigueGeneral disorders0/393/25
Upper respiratory tract infectionInfections and infestations4/392/25
Injection site erythemaGeneral disorders1/392/25
PyrexiaGeneral disorders1/392/25
NauseaGastrointestinal disorders0/392/25
Pain in extremityMusculoskeletal and connective tissue disorders0/392/25
NasopharyngitisInfections and infestations3/391/25
Gastrointestinal infectionInfections and infestations2/391/25

Baseline characteristics

ITT analysis set included all the randomized participants who provided written informed consent and underwent study screening procedures.

Age, Continuous
Age, Continuous(years)CSL312PlaceboTotal
Mean43.3 ± 17.4537.8 ± 12.8041.2 ± 15.92
Sex: Female, Male
Sex: Female, Male(Participants)CSL312PlaceboTotal
Female241438
Male151126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CSL312PlaceboTotal
Hispanic or Latino123
Not Hispanic or Latino372360
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CSL312PlaceboTotal
Race — Asian426
Race — Black or African American011
Race — Native Hawaiian or Other Pacific Islander101
Race — White332255
Race — Other101
Region of Enrollment
Region of Enrollment(participants)CSL312PlaceboTotal
Canada538
Netherlands213
Hungary202
United States12921
Japan426
Israel729
Germany7815
08

Study locations

28 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35209, United States
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • Raffi Tachdjian MD, Inc.
    Santa Monica, California 90404, United States
  • Allergy and Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • Institute of Asthma and Allergy
    Chevy Chase, Maryland 20815, United States
  • Bernstein Clinical Research Center LLC
    Cincinnati, Ohio 45231, United States
  • Pennsylvania State University
    Hershey, Pennsylvania 17033, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • University of Alberta - Research Transition Facility
    Edmonton, Alberta T6G 2B7, Canada
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1H 1E4, Canada
  • Gordon Sussman Clinical Research Inc.
    Toronto, Ontario M3B 3S6, Canada
  • Clinique specialisee en allergie de la Capitale
    Québec, G1V 4W2, Canada
  • Universitätsklinikum Frankfurt Goethe-Universität
    Frankfurt, Hessen 60590, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • CRC Clinical Research / Hautklinik und Poliklinik der Universitätsklinik Mainz
    Mainz, 55131, Germany
  • HZRM Hämophilie Zentrum Rhein Main GmbH
    Mörfelden-Walldorf, 64546, Germany
  • Semmelweis University
    Budapest, 1088, Hungary
  • Barzilai University Medical Center
    Ashkelon, 7830604, Israel
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima 734-8551, Japan
  • Kobe University Hospital
    Kobe-shi, Hyogo '650-0017, Japan
  • St.Marianna University School of Medicine Hospital
    Kawasaki-shi, Kanagawa 216-8511, Japan
  • Saitama Medical Center
    Saitama, Kawagoe-shi 350-8550, Japan
  • Saga University Hospital
    Saga, Saga-shi '849-8501, Japan
  • Koga Community Hospital
    Yaizu-shi, Shizuoka 425-0088, Japan
  • Juntendo University Hospital
    Bunkyo, Tokyo 113-8431, Japan
  • Saiyu Soka Hospital
    Saitama, 340-0041, Japan
  • Amsterdam UMC, Location AMC
    Amsterdam, 1105 AZ, Netherlands
09

References and documents

Publications

  • Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. PubMed 36326435 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2022, 16 months.

Results were first posted in Jun 2023, 1 year after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 7, 2020
StartActual
Jan 27, 2021
Primary completionActual
Jun 7, 2022
CompletionActual
Jun 7, 2022
Results first posted
Jun 29, 2023
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04656418
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Dec 7, 2020
Start date
Jan 27, 2021
Primary completion
Jun 7, 2022
Completion
Jun 7, 2022
Results posted
Jun 29, 2023
Last update
Jun 29, 2023

Study contacts

Study Director
study director · CSL Behring LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion